M. L. O'Donoghue Et Al. , "Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk Insights From the FOURIER Trial," CIRCULATION , vol.139, no.12, pp.1483-1492, 2019
O'Donoghue, M. L. Et Al. 2019. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk Insights From the FOURIER Trial. CIRCULATION , vol.139, no.12 , 1483-1492.
O'Donoghue, M. L., Fazio, S., Giugliano, R. P., Stroes, E. S. G., Kanevsky, E., Gouni-Berthold, I., ... Im, K.(2019). Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk Insights From the FOURIER Trial. CIRCULATION , vol.139, no.12, 1483-1492.
O'Donoghue, Michelle Et Al. "Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk Insights From the FOURIER Trial," CIRCULATION , vol.139, no.12, 1483-1492, 2019
O'Donoghue, Michelle L. Et Al. "Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk Insights From the FOURIER Trial." CIRCULATION , vol.139, no.12, pp.1483-1492, 2019
O'Donoghue, M. L. Et Al. (2019) . "Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk Insights From the FOURIER Trial." CIRCULATION , vol.139, no.12, pp.1483-1492.
@article{article, author={Michelle L. O'Donoghue Et Al. }, title={Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk Insights From the FOURIER Trial}, journal={CIRCULATION}, year=2019, pages={1483-1492} }